

Supplementary Table 1. Characteristics of randomized clinical trials included in meta-analysis

Study	Year	Experimental	Control	Background anti-diabetic mediations	Length of treatment	No. of participants
Barnett et al. [22]	2014	Empagliflozin	Placebo	Naïve	52 wk	290
Bailey et al. [23]	2013	Dapagliflozin	Placebo	Metformin	102 wk	546
Haering et al. [24]	2015	Empagliflozin	Placebo	Metformin, sulphonylurea	76 wk	666
Kaku et al. [21]	2017	Empagliflozin	Placebo	Various	Median: 2.6 yr	1,517
Kohan et al. [25]	2014	Dapagliflozin	Placebo	Insulin, sulphonylurea, thiazolidinedione	104 wk	252
Kovasc et al. [26]	2015	Empagliflozin	Placebo	Metformin, thiazolidinedione	76 wk	498
Merker et al. [27]	2015	Empagliflozin	Placebo	Metformin	76 wk	637
Roden et al. [28]	2015	Empagliflozin	Placebo, sitagliptin	Naïve	76 wk	676
Rosenstock et al. [29]	2015	Empagliflozin	Placebo	Insulin	78 wk	494
Wanner et al. [10]	2016	Empagliflozin	Placebo	Various	Median: 2.6 yr	7,020
Wilding et al. [30]	2014	Dapagliflozin	Placebo	Insulin	104 wk	800
Wiviott et al. [9]	2019	Dapagliflozin	Placebo	Various	Median: 4.2 yr	17,160